Skip to main content
Top
Published in: Current Psychiatry Reports 4/2012

01-08-2012 | Geriatric Disorders (DC Steffens, Section Editor)

Behavioral Disturbance in Dementia

Authors: Abhilash K. Desai, Lori Schwartz, George T. Grossberg

Published in: Current Psychiatry Reports | Issue 4/2012

Login to get access

Abstract

Behavioral disturbances are frequently the most challenging manifestations of dementia and are exhibited in almost all people with dementia. Common behavioral disturbances can be grouped into four categories: mood disorders (e.g., depression, apathy, euphoria); sleep disorders (insomnia, hypersomnia, night–day reversal); psychotic symptoms (delusions and hallucinations); and agitation (e.g., pacing, wandering, sexual disinhibition, aggression). They are often persistent, greatly diminish quality of life of patients and their family caregivers, cause premature institutionalization, and pose a high economic burden on the patient, family, and society. Behavioral disturbances can be prevented and treated with a multifaceted approach that supports dignity and promotes comfort and quality of life of persons with dementia and their family members. Management involves prompt treatment of reversible factors and management of symptoms using primarily individualized nonpharmacological interventions. Pharmacological interventions need to be restricted to behavioral emergencies and for short-term treatment of behavioral disturbances that pose imminent danger to self or others.
Literature
1.
go back to reference • Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2012;8:131–68. This reference provide the latest and most comprehensive statistics on prevalence of Alzheimer’s disease and behavioral disturbances. • Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2012;8:131–68. This reference provide the latest and most comprehensive statistics on prevalence of Alzheimer’s disease and behavioral disturbances.
3.
go back to reference Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157:708–14.PubMed Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157:708–14.PubMed
4.
go back to reference Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23:170–7.PubMed Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23:170–7.PubMed
5.
go back to reference Wetzels RB, Zuidema SU, de Jonghe JF, et al. Course of neuropsychiatric symptoms in residents with dementia in nursing homes over 2-year period. Am J Geriatr Psychiatry. 2010;18:1054–65.PubMed Wetzels RB, Zuidema SU, de Jonghe JF, et al. Course of neuropsychiatric symptoms in residents with dementia in nursing homes over 2-year period. Am J Geriatr Psychiatry. 2010;18:1054–65.PubMed
6.
go back to reference Wetzels R, Zuidema S, Jansen I, et al. Course of neuropsychiatric symptoms in residents with dementia in long-term care institutions: a systematic review. Int Psychogeriatr. 2010;22:1040–53.PubMed Wetzels R, Zuidema S, Jansen I, et al. Course of neuropsychiatric symptoms in residents with dementia in long-term care institutions: a systematic review. Int Psychogeriatr. 2010;22:1040–53.PubMed
7.
go back to reference Bergh S, Engedal K, Roen I, Selbaek G. The course of neuropsychiatric symptoms in patients with dementia in Norwegian nursing homes. Int Psychogeriatr. 2011;23:1231–9.PubMed Bergh S, Engedal K, Roen I, Selbaek G. The course of neuropsychiatric symptoms in patients with dementia in Norwegian nursing homes. Int Psychogeriatr. 2011;23:1231–9.PubMed
8.
go back to reference Borroni B, Agosti C, Padovani A. Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): Frequency and relationship with disease severity and motor impairment. Arch Gerontol Geriatrics. 2008;46:101–6. Borroni B, Agosti C, Padovani A. Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): Frequency and relationship with disease severity and motor impairment. Arch Gerontol Geriatrics. 2008;46:101–6.
9.
go back to reference Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs. 2010;24:375–98.PubMed Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs. 2010;24:375–98.PubMed
10.
go back to reference Moorhouse P, Rockwood K. Vascular cognitive impairment: current concepts and clinical development. Lancet Neurol. 2008;7:246–55.PubMed Moorhouse P, Rockwood K. Vascular cognitive impairment: current concepts and clinical development. Lancet Neurol. 2008;7:246–55.PubMed
11.
go back to reference Robottom BJ, Weiner WJ. Dementia in Parkinson’s disease. Int Rev Neurobiol. 2009;84:229–44.PubMed Robottom BJ, Weiner WJ. Dementia in Parkinson’s disease. Int Rev Neurobiol. 2009;84:229–44.PubMed
12.
go back to reference Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD. The diagnosis of young-onset dementia. Lancet Neurol. 2010;9:793–806.PubMed Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD. The diagnosis of young-onset dementia. Lancet Neurol. 2010;9:793–806.PubMed
13.
go back to reference Rosenblatt A, Samus QM, Steele CD, et al. The Maryland assisted living study: prevalence, recognition, and treatment of dementia and other psychiatric disorders in the assisted living population of central Maryland. J Am Geriatr Soc. 2004;52:1618–25.PubMed Rosenblatt A, Samus QM, Steele CD, et al. The Maryland assisted living study: prevalence, recognition, and treatment of dementia and other psychiatric disorders in the assisted living population of central Maryland. J Am Geriatr Soc. 2004;52:1618–25.PubMed
14.
go back to reference Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer’s disease: a natural history study. J Am Geriatr Soc. 1996;44:1078–81.PubMed Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer’s disease: a natural history study. J Am Geriatr Soc. 1996;44:1078–81.PubMed
15.
go back to reference Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288:1475–83.PubMed Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288:1475–83.PubMed
16.
go back to reference Apostolova LG, Cummings JL. Neuropsychiatric manifestations in mild cognitive impairment. A systematic review of the literature. Dement Geriatr Cogn Disord. 2008;25:115–26.PubMed Apostolova LG, Cummings JL. Neuropsychiatric manifestations in mild cognitive impairment. A systematic review of the literature. Dement Geriatr Cogn Disord. 2008;25:115–26.PubMed
17.
go back to reference Sultzer DL, Levin HS, Mahler ME, et al. A comparison of psychiatric symptoms in vascular dementia and Alzheimer’s disease. Am J Psychiatry. 1993;150:1806–12.PubMed Sultzer DL, Levin HS, Mahler ME, et al. A comparison of psychiatric symptoms in vascular dementia and Alzheimer’s disease. Am J Psychiatry. 1993;150:1806–12.PubMed
18.
go back to reference Forsell Y, Winblad B. Major depression in a population of demented and nondemented older people: Prevalence and correlates. J Am Geriatr Soc. 1998;46:27–30.PubMed Forsell Y, Winblad B. Major depression in a population of demented and nondemented older people: Prevalence and correlates. J Am Geriatr Soc. 1998;46:27–30.PubMed
19.
go back to reference McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863–72.PubMed McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863–72.PubMed
20.
go back to reference Tucker I. Management of inappropriate sexual behaviors in dementia: a literature review. Int Psychogeriatr. 2010;22:683–92.PubMed Tucker I. Management of inappropriate sexual behaviors in dementia: a literature review. Int Psychogeriatr. 2010;22:683–92.PubMed
21.
go back to reference Chow TW, Binns MA, Cummings JL, et al. Apathy symptom profile and behavioral associations in frontotemporal vs. Alzheimer’s disease. Arch Neurol. 2009;66:888–93.PubMed Chow TW, Binns MA, Cummings JL, et al. Apathy symptom profile and behavioral associations in frontotemporal vs. Alzheimer’s disease. Arch Neurol. 2009;66:888–93.PubMed
22.
go back to reference Robert PH, Clairet S, Benoit M, et al. The Apathy Inventory: assessment of apathy and awareness in Alzheimer’s disease, Parkinson’s disease and mild cognitive impairment. Int J Geriatr Psychiatry. 2002;17:1099–105.PubMed Robert PH, Clairet S, Benoit M, et al. The Apathy Inventory: assessment of apathy and awareness in Alzheimer’s disease, Parkinson’s disease and mild cognitive impairment. Int J Geriatr Psychiatry. 2002;17:1099–105.PubMed
23.
go back to reference Srikanth S, Nagaraja AV, Ratnavalli E. Neuropsychiatric symptoms in dementia – frequency, relationship to dementia severity and comparison in Alzheimer’s disease, vascular dementia and frontotemporal dementia. J Neurol Sci. 2005;236:43–8.PubMed Srikanth S, Nagaraja AV, Ratnavalli E. Neuropsychiatric symptoms in dementia – frequency, relationship to dementia severity and comparison in Alzheimer’s disease, vascular dementia and frontotemporal dementia. J Neurol Sci. 2005;236:43–8.PubMed
24.
go back to reference Steffens DC, Otey E, Alexopoulos GS, et al. Perspectives on depression, mild cognitive impairment, and cognitive decline. Arch Gen Psychiatry. 2006;63:130–8.PubMed Steffens DC, Otey E, Alexopoulos GS, et al. Perspectives on depression, mild cognitive impairment, and cognitive decline. Arch Gen Psychiatry. 2006;63:130–8.PubMed
25.
go back to reference Rubin EH, Veiel LL, Kinscherf DA, et al. Clinically significant depressive symptoms in very mild to mild dementia of the Alzheimer’s type. Int J Geriatr Psychiatry. 2001;16:694–701.PubMed Rubin EH, Veiel LL, Kinscherf DA, et al. Clinically significant depressive symptoms in very mild to mild dementia of the Alzheimer’s type. Int J Geriatr Psychiatry. 2001;16:694–701.PubMed
26.
go back to reference Baldini-Gruber A, Zimmerman S, Boustani M, et al. Characteristics associated with depression in long-term care residents with dementia. Gerontologist. 2005;45:50–5. Baldini-Gruber A, Zimmerman S, Boustani M, et al. Characteristics associated with depression in long-term care residents with dementia. Gerontologist. 2005;45:50–5.
27.
go back to reference Lyketsos CG, Steele C, Galik E, et al. Physical aggression in dementia patients and its relationship to depression. Am J Psychiatry. 1999;156:66–71.PubMed Lyketsos CG, Steele C, Galik E, et al. Physical aggression in dementia patients and its relationship to depression. Am J Psychiatry. 1999;156:66–71.PubMed
28.
go back to reference Cummings JL. Behavioral and neuropsychiatric outcomes in Alzheimer’s disease. CNS Spectr. 2005;10 Suppl 18:22–5.PubMed Cummings JL. Behavioral and neuropsychiatric outcomes in Alzheimer’s disease. CNS Spectr. 2005;10 Suppl 18:22–5.PubMed
29.
go back to reference Hoe J, Hancock G, Livingston G, Orrell M. Quality of Life of people with dementia in residential care homes. Br J Psychiatry. 2006;188:460–4.PubMed Hoe J, Hancock G, Livingston G, Orrell M. Quality of Life of people with dementia in residential care homes. Br J Psychiatry. 2006;188:460–4.PubMed
30.
go back to reference Selbaek G, Engedal K. Stability of the factor structure of the Neuropsychiatric Inventory in a 31-month follow-up study of a large sample of nursing-home patients with dementia. Int Psychogeriatr. 2012;24:62–73.PubMed Selbaek G, Engedal K. Stability of the factor structure of the Neuropsychiatric Inventory in a 31-month follow-up study of a large sample of nursing-home patients with dementia. Int Psychogeriatr. 2012;24:62–73.PubMed
31.
go back to reference Spalletta G, Musicco M. Padovani, et al. Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease. Am J Geriatr Psychiatry. 2010;18:1026–35.PubMed Spalletta G, Musicco M. Padovani, et al. Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease. Am J Geriatr Psychiatry. 2010;18:1026–35.PubMed
32.
go back to reference Cohen-Mansfield J, Billig N. Agitated behaviors in the elderly: a conceptual review. J Am Geriatr Soc. 1986;34:711–21.PubMed Cohen-Mansfield J, Billig N. Agitated behaviors in the elderly: a conceptual review. J Am Geriatr Soc. 1986;34:711–21.PubMed
33.
go back to reference Leonard R, Tinneti ME, Allore HG, et al. Potentially modifiable resident characteristics that are associated with physical or verbal aggression among nursing home residents with dementia. Arch Intern Med. 2006;166:1295–300.PubMed Leonard R, Tinneti ME, Allore HG, et al. Potentially modifiable resident characteristics that are associated with physical or verbal aggression among nursing home residents with dementia. Arch Intern Med. 2006;166:1295–300.PubMed
34.
go back to reference Robinson L, Hutchings D, Dickinson HO, et al. Effectiveness and acceptance of non-pharmacological interventions to reduce wandering in dementia: a systematic review. Int J Geriatr Psychiatry. 2007;22:9–22.PubMed Robinson L, Hutchings D, Dickinson HO, et al. Effectiveness and acceptance of non-pharmacological interventions to reduce wandering in dementia: a systematic review. Int J Geriatr Psychiatry. 2007;22:9–22.PubMed
35.
go back to reference Lantz M. Wandering in dementia. Clin Geriatrics. 2007;15:21–4. Lantz M. Wandering in dementia. Clin Geriatrics. 2007;15:21–4.
36.
go back to reference Khachiyants N, Trinkle D, Son SJ, Kim KY. Sundown syndrome in persons with dementia: an update. Psychiatry Investig. 2011;8:275–87.PubMed Khachiyants N, Trinkle D, Son SJ, Kim KY. Sundown syndrome in persons with dementia: an update. Psychiatry Investig. 2011;8:275–87.PubMed
37.
go back to reference Bombois S, Derambure P, Pasquire F, Monaca C. Sleep disorders in aging and dementia. J Nutr Health Aging. 2010;14:212–7.PubMed Bombois S, Derambure P, Pasquire F, Monaca C. Sleep disorders in aging and dementia. J Nutr Health Aging. 2010;14:212–7.PubMed
38.
go back to reference Boeve BF. REM Sleep Behavior Disorder: Update review of the core features, the RBD-Neurodegenerative Disease Association. Evolving concepts, controversies, and future directions. Ann N Y Acad Sci. 2010;1184:15–54.PubMed Boeve BF. REM Sleep Behavior Disorder: Update review of the core features, the RBD-Neurodegenerative Disease Association. Evolving concepts, controversies, and future directions. Ann N Y Acad Sci. 2010;1184:15–54.PubMed
39.
go back to reference Ropacki S, Jeste D. Epidemiology of and risk factors for psychosis of Alzheimer’s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162:2022–30.PubMed Ropacki S, Jeste D. Epidemiology of and risk factors for psychosis of Alzheimer’s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162:2022–30.PubMed
40.
go back to reference Johnson D, Watts A, Chapin B, et al. Neuropsychiatric profiles in dementia. Alzheimer Dis Assoc Disord. 2011;25:326–32.PubMed Johnson D, Watts A, Chapin B, et al. Neuropsychiatric profiles in dementia. Alzheimer Dis Assoc Disord. 2011;25:326–32.PubMed
41.
go back to reference Bassiony MM, Lyketsos CG. Delusions and hallucinations in Alzheimer’s Disease: review of the brain decade. Psychosomatics. 2003;44:388–401.PubMed Bassiony MM, Lyketsos CG. Delusions and hallucinations in Alzheimer’s Disease: review of the brain decade. Psychosomatics. 2003;44:388–401.PubMed
42.
go back to reference Woods DL, Phillips LR, Martin JL. Biological basis for sleep disturbance and behavioral symptoms in dementia: a biobehavioral model. Res Gerontol Nurs. 2011;4:281–93.PubMed Woods DL, Phillips LR, Martin JL. Biological basis for sleep disturbance and behavioral symptoms in dementia: a biobehavioral model. Res Gerontol Nurs. 2011;4:281–93.PubMed
43.
go back to reference Zarros AC, Kalopita KS, Tsakiris ST. Serotoninergic impairment and aggressive behavior in Alzheimer’s disease. Acta Neurobiol Exp (Wars). 2005;65:277–86. Zarros AC, Kalopita KS, Tsakiris ST. Serotoninergic impairment and aggressive behavior in Alzheimer’s disease. Acta Neurobiol Exp (Wars). 2005;65:277–86.
44.
go back to reference Day K, Carreon D, Stump C. The therapeutic design of environments for people with dementia: a review of the empirical research. Gerontologist. 2000;40:397–416.PubMed Day K, Carreon D, Stump C. The therapeutic design of environments for people with dementia: a review of the empirical research. Gerontologist. 2000;40:397–416.PubMed
45.
go back to reference Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer’s disease. Am J Geriatr Psychiatry. 1998;6 Suppl 1:64–8. Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer’s disease. Am J Geriatr Psychiatry. 1998;6 Suppl 1:64–8.
46.
go back to reference Lancot KL, Hermann N, van Reekum R, et al. Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzhiemer’s disease. Int J Geriatr Psychiatry. 2002;17:531–41. Lancot KL, Hermann N, van Reekum R, et al. Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzhiemer’s disease. Int J Geriatr Psychiatry. 2002;17:531–41.
47.
go back to reference Baldessarini RJ, March ER, Kula NS. Interactions of fluoxetine with metabolism of dopamine and serotonin in rat brain regions. Brain Res. 1992;579:152–6.PubMed Baldessarini RJ, March ER, Kula NS. Interactions of fluoxetine with metabolism of dopamine and serotonin in rat brain regions. Brain Res. 1992;579:152–6.PubMed
48.
go back to reference Zubenko GS, Moossy J, Martinez J, et al. Neurropatholic and neurochemical correlates of psychosis in primary dementia. Arch Neurol. 1991;48:619–24.PubMed Zubenko GS, Moossy J, Martinez J, et al. Neurropatholic and neurochemical correlates of psychosis in primary dementia. Arch Neurol. 1991;48:619–24.PubMed
49.
go back to reference Lopez OL, Smith G, Becker JT, et al. The psychotic phenomenon in probable Alzhiemer’s disease: a positron emission tomography study. J Neuropsychiatry Clin Neurosci. 2001;13:50–5.PubMed Lopez OL, Smith G, Becker JT, et al. The psychotic phenomenon in probable Alzhiemer’s disease: a positron emission tomography study. J Neuropsychiatry Clin Neurosci. 2001;13:50–5.PubMed
50.
go back to reference Marra C, Quaranta D, Profice P, et al. Central cholinergic dysfunction measured “in vivo” correlates with different behavioral disorders in Alzheimer’s disease and dementia with Lewy body. Brain Stimul. 2011. doi:10.1016/j.brs.2011.08.009. Marra C, Quaranta D, Profice P, et al. Central cholinergic dysfunction measured “in vivo” correlates with different behavioral disorders in Alzheimer’s disease and dementia with Lewy body. Brain Stimul. 2011. doi:10.​1016/​j.​brs.​2011.​08.​009.
51.
go back to reference Holmes C, Smith H, Ganderton R, et al. Psychosis and aggression in Alzhiemer’s disease: the effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry. 2001;71:777–9.PubMed Holmes C, Smith H, Ganderton R, et al. Psychosis and aggression in Alzhiemer’s disease: the effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry. 2001;71:777–9.PubMed
52.
go back to reference Sukonick DL, Pollock BG, Sweet RA, et al. The 5-HTTPR *S/*L polymorphism and aggressive behavior in Alzheimer’s disease. Arch Neurol. 2001;58:1425–8.PubMed Sukonick DL, Pollock BG, Sweet RA, et al. The 5-HTTPR *S/*L polymorphism and aggressive behavior in Alzheimer’s disease. Arch Neurol. 2001;58:1425–8.PubMed
53.
go back to reference Cohen-Mansfield J, Marx MS, Freedman LS, et al. The Comprehensive Process Model of Engagement. Am J Geriatr Psychiatry. 2011;19:859–70.PubMed Cohen-Mansfield J, Marx MS, Freedman LS, et al. The Comprehensive Process Model of Engagement. Am J Geriatr Psychiatry. 2011;19:859–70.PubMed
54.
go back to reference Pitfield C, Shahriyarmolki K, Livingston G. A systematic review of stress in staff caring for people with dementia living in 24-hour care settings. Int Psychogeriatr. 2011;23:4–9.PubMed Pitfield C, Shahriyarmolki K, Livingston G. A systematic review of stress in staff caring for people with dementia living in 24-hour care settings. Int Psychogeriatr. 2011;23:4–9.PubMed
55.
go back to reference Orrell M, Hancock GA, Galboda KC, et al. The needs of people with dementia in care homes: the perspectives of users, staff and family caregivers. Int Psychogeriatr. 2008;20:941–51.PubMed Orrell M, Hancock GA, Galboda KC, et al. The needs of people with dementia in care homes: the perspectives of users, staff and family caregivers. Int Psychogeriatr. 2008;20:941–51.PubMed
56.
go back to reference van der Roest HG, Meiland FJM, Maroccini R, et al. Subjective needs in people with dementia: a review of the literature. Int Psychogeriatr. 2007;19:559–92.PubMed van der Roest HG, Meiland FJM, Maroccini R, et al. Subjective needs in people with dementia: a review of the literature. Int Psychogeriatr. 2007;19:559–92.PubMed
57.
go back to reference Luo H, Lin M, Castle N. Physical restraint use and falls in nursing homes: A comparison between residents with and without dementia. Am J Alzheimers Dis Other Demen. 2011;26:44–50.PubMed Luo H, Lin M, Castle N. Physical restraint use and falls in nursing homes: A comparison between residents with and without dementia. Am J Alzheimers Dis Other Demen. 2011;26:44–50.PubMed
58.
go back to reference Scherder EJA, Bogen T, Eggermont LHP, et al. The more physical inactivity, the more agitation in dementia. Int Psychogeriatr. 2010;22:1203–8.PubMed Scherder EJA, Bogen T, Eggermont LHP, et al. The more physical inactivity, the more agitation in dementia. Int Psychogeriatr. 2010;22:1203–8.PubMed
59.
go back to reference Wang WW, Moyle W. Physical restraint use on people with dementia. A review of literature. Aust J Adv Nurs. 2005;22:46–52.PubMed Wang WW, Moyle W. Physical restraint use on people with dementia. A review of literature. Aust J Adv Nurs. 2005;22:46–52.PubMed
60.
go back to reference Ballard C, Fossey J, Chithramohan R, et al. Quality of care in people with dementia in private sector and NHS facilities for people with dementia: cross sectional survey. BMJ. 2001;323:426–7.PubMed Ballard C, Fossey J, Chithramohan R, et al. Quality of care in people with dementia in private sector and NHS facilities for people with dementia: cross sectional survey. BMJ. 2001;323:426–7.PubMed
61.
go back to reference Morley J. Dementia-related agitation. JAMDA. 2011;12:611–2. Morley J. Dementia-related agitation. JAMDA. 2011;12:611–2.
62.
go back to reference Desai AK. Psychotropic side effects of commonly prescribed drugs in the elderly. Primary Psychiatry. 2004;11:27–34. Desai AK. Psychotropic side effects of commonly prescribed drugs in the elderly. Primary Psychiatry. 2004;11:27–34.
63.
go back to reference Fick DM, Agostini JV, Inouye SK. Delirium superimposed on dementia: A systematic review. J Am Geriatr Soc. 2002;50:1723–32.PubMed Fick DM, Agostini JV, Inouye SK. Delirium superimposed on dementia: A systematic review. J Am Geriatr Soc. 2002;50:1723–32.PubMed
64.
go back to reference Buffum MD, Hutt E, Chang VT, et al. Cognitive impairment and pain management: Review of issues and challenges. J Rehabil Res Dev. 2007;44:315–30.PubMed Buffum MD, Hutt E, Chang VT, et al. Cognitive impairment and pain management: Review of issues and challenges. J Rehabil Res Dev. 2007;44:315–30.PubMed
65.
go back to reference Bourbonnais A, Ducharme F. The meanings of screams in older people living with dementia in a nursing home. Int Psychogeriatr. 2010;22:1172–84.PubMed Bourbonnais A, Ducharme F. The meanings of screams in older people living with dementia in a nursing home. Int Psychogeriatr. 2010;22:1172–84.PubMed
66.
go back to reference Koppel J, Goldberg TE, Gordon ML, et al. Relationships between behavioral syndromes and cognitive domains in Alzheimer’s disease: the impact of mood and psychosis. Am J Geriatr Psychiatry. 2011. doi:10.1097/JGP.0b013e3182358921 Koppel J, Goldberg TE, Gordon ML, et al. Relationships between behavioral syndromes and cognitive domains in Alzheimer’s disease: the impact of mood and psychosis. Am J Geriatr Psychiatry. 2011. doi:10.​1097/​JGP.​0b013e3182358921​
67.
go back to reference Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease. Am J Psychiatry. 1990;147:1049–51.PubMed Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease. Am J Psychiatry. 1990;147:1049–51.PubMed
68.
go back to reference Mohamed S, Rosenheck R, Lyketsos CG, Schneider LS. Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates. Am J Geriatr Psychiatry. 2010;18:917–27.PubMed Mohamed S, Rosenheck R, Lyketsos CG, Schneider LS. Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates. Am J Geriatr Psychiatry. 2010;18:917–27.PubMed
69.
go back to reference Hermann N, Lanctot KL, Sambrook R, et al. The contribution of neuropsychiatric symptoms to the cost of dementia care. Int J Geriatr Psychiatry. 2006;21:972–6. Hermann N, Lanctot KL, Sambrook R, et al. The contribution of neuropsychiatric symptoms to the cost of dementia care. Int J Geriatr Psychiatry. 2006;21:972–6.
70.
go back to reference Matsumoto N, Ikeda M, Fukuhara R, et al. Caregiver burden associated with behavioral and psychological symptoms of dementia in elderly people in the local community. Dement Geriatr Cogn Disord. 2007;23:219–24.PubMed Matsumoto N, Ikeda M, Fukuhara R, et al. Caregiver burden associated with behavioral and psychological symptoms of dementia in elderly people in the local community. Dement Geriatr Cogn Disord. 2007;23:219–24.PubMed
71.
go back to reference Craig D, Mirakhur A, Hart DJ, et al. A cross sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer’s disease. Am J Geriatr Psychiatry. 2005;13:460–8.PubMed Craig D, Mirakhur A, Hart DJ, et al. A cross sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer’s disease. Am J Geriatr Psychiatry. 2005;13:460–8.PubMed
72.
go back to reference Stern Y, Tang MX, Albert SM, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA. 1997;227:806–12. Stern Y, Tang MX, Albert SM, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA. 1997;227:806–12.
73.
go back to reference Bergvall N, Brinck P, Eek D, et al. Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer’s disease. Int Psychogeriatr. 2011;23:73–85.PubMed Bergvall N, Brinck P, Eek D, et al. Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer’s disease. Int Psychogeriatr. 2011;23:73–85.PubMed
74.
go back to reference Svanberg E, Spector A, Stott J. The impact of young onset dementia on the family: a literature review. Int Psychogeriatr. 2011;23:356–71.PubMed Svanberg E, Spector A, Stott J. The impact of young onset dementia on the family: a literature review. Int Psychogeriatr. 2011;23:356–71.PubMed
75.
go back to reference Lee DR, Thomas AJ. Sleep in dementia and caregiving – assessment and treatment implications: a review. Int Psychogeriatr. 2011;23:190–201.PubMed Lee DR, Thomas AJ. Sleep in dementia and caregiving – assessment and treatment implications: a review. Int Psychogeriatr. 2011;23:190–201.PubMed
76.
go back to reference O’Donnell BF, Drachman DA, Barnes HJ, et al. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol. 1992;5:45–52.PubMed O’Donnell BF, Drachman DA, Barnes HJ, et al. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol. 1992;5:45–52.PubMed
77.
go back to reference Miller EA, Schneider LS, Rosenheck RA. Predictors of nursing home admission among Alzheimer’s disease patients with psychosis and/or agitation. Int Psychogeriatr. 2011;23:44–53.PubMed Miller EA, Schneider LS, Rosenheck RA. Predictors of nursing home admission among Alzheimer’s disease patients with psychosis and/or agitation. Int Psychogeriatr. 2011;23:44–53.PubMed
78.
go back to reference Chung JCC, Lai CKY. Elopement among community-dwelling older adults with dementia. Int Psychogeriatr. 2011;23:65–72.PubMed Chung JCC, Lai CKY. Elopement among community-dwelling older adults with dementia. Int Psychogeriatr. 2011;23:65–72.PubMed
79.
go back to reference Coen RF, Swanwick GR, O’Boyle CA, Coakley D. Behaviour disturbances and other predictors of carer burden in Alzheimer’s disease. Int J Geriatr Psychiatry. 1997;12:331–6.PubMed Coen RF, Swanwick GR, O’Boyle CA, Coakley D. Behaviour disturbances and other predictors of carer burden in Alzheimer’s disease. Int J Geriatr Psychiatry. 1997;12:331–6.PubMed
80.
go back to reference Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer’s disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998;46:210–5.PubMed Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer’s disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998;46:210–5.PubMed
81.
go back to reference Beeri MS, Werner P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer’s disease patients. Int J Geriatr Psychiatry. 2002;17:403–8.PubMed Beeri MS, Werner P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer’s disease patients. Int J Geriatr Psychiatry. 2002;17:403–8.PubMed
82.
go back to reference Grossberg GT, Desai AK. Management of Alzheimer’s disease. J Gerontol Med Sci. 2003;58A:331–53. Grossberg GT, Desai AK. Management of Alzheimer’s disease. J Gerontol Med Sci. 2003;58A:331–53.
83.
go back to reference Passmore MJ, Ho A, Gallagher R. Behavioral and psychological symptoms in moderate to severe Alzheimer’s disease: A palliative care approach emphasizing recognition of personhood and preservation of dignity. J Alzheimer Dis. 2012;29:1–13. Passmore MJ, Ho A, Gallagher R. Behavioral and psychological symptoms in moderate to severe Alzheimer’s disease: A palliative care approach emphasizing recognition of personhood and preservation of dignity. J Alzheimer Dis. 2012;29:1–13.
84.
go back to reference • Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in Alzheimer’s disease. Int Psychogeriatr. 2010;22:346–72. A most recent review on the management of behavioral disturbances in patients with Alzheimer’s disease.PubMed • Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in Alzheimer’s disease. Int Psychogeriatr. 2010;22:346–72. A most recent review on the management of behavioral disturbances in patients with Alzheimer’s disease.PubMed
85.
go back to reference Lyketsos CG, Carrillo MC, Ryan JM, et al. Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimer Dement. 2011;7:532–9. Lyketsos CG, Carrillo MC, Ryan JM, et al. Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimer Dement. 2011;7:532–9.
86.
go back to reference Koopmans RTC, Zuidema SU, Leontjevas R, Gerritsen DL. Comprehensive assessment of depression and behavioral problems in long-term care. Int Psychogeriatr. 2010;23:1054–62. Koopmans RTC, Zuidema SU, Leontjevas R, Gerritsen DL. Comprehensive assessment of depression and behavioral problems in long-term care. Int Psychogeriatr. 2010;23:1054–62.
87.
go back to reference Desai AK, Grossberg GT. Management of Alzheimer’s disease. J Gerontol Med Sci. 2003;58A:331–53. Desai AK, Grossberg GT. Management of Alzheimer’s disease. J Gerontol Med Sci. 2003;58A:331–53.
88.
go back to reference Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–14.PubMed Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–14.PubMed
89.
go back to reference Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry. 1987;48:9–15.PubMed Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry. 1987;48:9–15.PubMed
90.
go back to reference Jeon YH, Sansoni J, Low LF, et al. Recommended measures for the assessment of behavioral disturbances associated with dementia. Am J Geriatr Psychiatry. 2011;19:403–15.PubMed Jeon YH, Sansoni J, Low LF, et al. Recommended measures for the assessment of behavioral disturbances associated with dementia. Am J Geriatr Psychiatry. 2011;19:403–15.PubMed
91.
go back to reference Alexopoulos GS, Abrams RC, Young RC, et al. Cornell scale for depression in dementia. Biol Psychiatry. 1988;23:271–84.PubMed Alexopoulos GS, Abrams RC, Young RC, et al. Cornell scale for depression in dementia. Biol Psychiatry. 1988;23:271–84.PubMed
93.
go back to reference Rabins PV, Blacker D, Rovner BW, et al. APA Work Group on Alzheimer’s Disease and other Dementias. American Psychiatric Association practice guidelines for the treatment of patients with Alzheimer’s disease and other dementias. Second edition. Am J Psychiatry. 2007;164 Suppl 12:5–56.PubMed Rabins PV, Blacker D, Rovner BW, et al. APA Work Group on Alzheimer’s Disease and other Dementias. American Psychiatric Association practice guidelines for the treatment of patients with Alzheimer’s disease and other dementias. Second edition. Am J Psychiatry. 2007;164 Suppl 12:5–56.PubMed
94.
go back to reference Cohen-Mansfield L, Libin A, Marx MS. Nonpharmacological treatment of agitation: a controlled trial of systematic individualized intervention. Gerontol A Biol Sci Med Sci. 2007;62:908–16. Cohen-Mansfield L, Libin A, Marx MS. Nonpharmacological treatment of agitation: a controlled trial of systematic individualized intervention. Gerontol A Biol Sci Med Sci. 2007;62:908–16.
95.
go back to reference Manepalli J, Desai A, Sharma P. Psychosocial-environmental treatments for Alzheimer’s disease. Primary Psychiatry. 2009;16:39–47. Manepalli J, Desai A, Sharma P. Psychosocial-environmental treatments for Alzheimer’s disease. Primary Psychiatry. 2009;16:39–47.
96.
go back to reference Edwardsson D, Winblad B, Sandman PO. Person centered care of people with severe Alzheimer’s disease: Current status and ways forward. Lancet Neurol. 2008;7:362–7. Edwardsson D, Winblad B, Sandman PO. Person centered care of people with severe Alzheimer’s disease: Current status and ways forward. Lancet Neurol. 2008;7:362–7.
97.
go back to reference O’Neil ME, Freeman M, Christensen V, et al. A systematic evidence review of non-pharmacological interventions for behavioral symptoms of dementia. VA Evidence-based Synthesis Program Reports. 2011. O’Neil ME, Freeman M, Christensen V, et al. A systematic evidence review of non-pharmacological interventions for behavioral symptoms of dementia. VA Evidence-based Synthesis Program Reports. 2011.
98.
go back to reference Tune LE. Nonpharmacological treatment of inappropriate sexual behaviors in dementia: the case of the Pink Panther. Am J Geriatr Psychiatry. 2008;16:612–6.PubMed Tune LE. Nonpharmacological treatment of inappropriate sexual behaviors in dementia: the case of the Pink Panther. Am J Geriatr Psychiatry. 2008;16:612–6.PubMed
99.
go back to reference Olazaran J, Reisberg B, Clare L, et al. Nonpharmacological therapies in Alzheimer’s disease: A systematic review of efficacy. Dement Geritr Cogn Disord. 2010;30:161–78. Olazaran J, Reisberg B, Clare L, et al. Nonpharmacological therapies in Alzheimer’s disease: A systematic review of efficacy. Dement Geritr Cogn Disord. 2010;30:161–78.
100.
go back to reference Vernooij-Dassen M, Vasse E, Zuidema S, et al. Psychosocial interventions for dementia patients in long-term care. Int Psychogeriatr. 2010;22:1121–8.PubMed Vernooij-Dassen M, Vasse E, Zuidema S, et al. Psychosocial interventions for dementia patients in long-term care. Int Psychogeriatr. 2010;22:1121–8.PubMed
101.
go back to reference •• Kverno KS, Black BS, Nolan MT, Rabin PV. Research on treating neuropsychiatric symptoms of advanced dementia with non-pharmacological strategies, 1998–2008: a systematic literature review. Int Psychogeriatr. 2009;21:825–43. Excellent review of the literature on the efficacy of non-pharmacological strategies for the treatment of behavioral disturbances in patients with advanced dementia.PubMed •• Kverno KS, Black BS, Nolan MT, Rabin PV. Research on treating neuropsychiatric symptoms of advanced dementia with non-pharmacological strategies, 1998–2008: a systematic literature review. Int Psychogeriatr. 2009;21:825–43. Excellent review of the literature on the efficacy of non-pharmacological strategies for the treatment of behavioral disturbances in patients with advanced dementia.PubMed
102.
go back to reference Forbes D, Culum I, Lischka AR, et al. Light therapy for managing cognitive, sleep, functional behavioural, or psychiatric disturbances in dementia. Cochane Database Syst Rev. 2009;(4):CD003946. Forbes D, Culum I, Lischka AR, et al. Light therapy for managing cognitive, sleep, functional behavioural, or psychiatric disturbances in dementia. Cochane Database Syst Rev. 2009;(4):CD003946.
103.
go back to reference der Lek RF Riemersma-van, Swaab DF, Twisk J, et al. Effect of bright light and melatonin on cognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA. 2008;299:2642–55. der Lek RF Riemersma-van, Swaab DF, Twisk J, et al. Effect of bright light and melatonin on cognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA. 2008;299:2642–55.
104.
go back to reference Mossello E, Ridolfi A, Mello AM, et al. Animal-assisted activity and emotional status of patients with Alzheimer’s disease in day care. Int Psychogeriatr. 2011;23:899–905. Mossello E, Ridolfi A, Mello AM, et al. Animal-assisted activity and emotional status of patients with Alzheimer’s disease in day care. Int Psychogeriatr. 2011;23:899–905.
105.
go back to reference Smith M, Kolanowski A, Buettner LL, Buckwalter KC. Beyond bingo: meaningful activities for persons with dementia in nursing homes. Ann Long Term Care. 2009;17:22–30. Smith M, Kolanowski A, Buettner LL, Buckwalter KC. Beyond bingo: meaningful activities for persons with dementia in nursing homes. Ann Long Term Care. 2009;17:22–30.
106.
go back to reference Kolanowski A, Fick D, Waller JL, Ahern F. Outcomes of antipsychotic drug use in community-dwelling elders with dementia. Arch Psychiatr Nurs. 2006;20:217–25.PubMed Kolanowski A, Fick D, Waller JL, Ahern F. Outcomes of antipsychotic drug use in community-dwelling elders with dementia. Arch Psychiatr Nurs. 2006;20:217–25.PubMed
107.
go back to reference Kovach CR, Taneli Y, Dohearty P, et al. Effect of the BACE intervention on agitation of people with dementia. Gerontologist. 2004;44:797–806.PubMed Kovach CR, Taneli Y, Dohearty P, et al. Effect of the BACE intervention on agitation of people with dementia. Gerontologist. 2004;44:797–806.PubMed
108.
go back to reference Graff MJL, Vernooij-Dassen MJM, Thijssen M, et al. Effects of community occupational therapy on quality of life, mood, and health status in dementia patients and their caregivers: a randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2007;62:1002–9.PubMed Graff MJL, Vernooij-Dassen MJM, Thijssen M, et al. Effects of community occupational therapy on quality of life, mood, and health status in dementia patients and their caregivers: a randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2007;62:1002–9.PubMed
109.
go back to reference Volicer L, Simard J, Pupa JH, Medrek R, Riordan ME. Effects of continuous activity programming on the behavioral symptoms of dementia. J Am Med Direct Assoc. 2006;7:426–31. Volicer L, Simard J, Pupa JH, Medrek R, Riordan ME. Effects of continuous activity programming on the behavioral symptoms of dementia. J Am Med Direct Assoc. 2006;7:426–31.
110.
go back to reference Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary and critique. Am J Geriatr Psychiatry. 2001;9:361–82.PubMed Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary and critique. Am J Geriatr Psychiatry. 2001;9:361–82.PubMed
111.
go back to reference Teri L, Logsdon RG, Uomoto J, McCurry SM. Behavioral treatment of depression in dementia patients: a controlled clinical trial. J Gerontol Psychol Sci Soc Sci. 1997;52:159–66. Teri L, Logsdon RG, Uomoto J, McCurry SM. Behavioral treatment of depression in dementia patients: a controlled clinical trial. J Gerontol Psychol Sci Soc Sci. 1997;52:159–66.
112.
go back to reference Chenoweth L, King MT, Jeon YH, et al. Caring for aged dementia care resident study (CADRES) of person-centered care, dementia-care mapping, and usual care in dementia: a cluster-randomized trial. Lancet Neurol. 2009;8:317–25.PubMed Chenoweth L, King MT, Jeon YH, et al. Caring for aged dementia care resident study (CADRES) of person-centered care, dementia-care mapping, and usual care in dementia: a cluster-randomized trial. Lancet Neurol. 2009;8:317–25.PubMed
113.
go back to reference Landau R, Werner S. Ethical aspects of using GPS for tracking people with dementia: recommendations for practice. Int Psychogeriatr. 2012;24:358–66.PubMed Landau R, Werner S. Ethical aspects of using GPS for tracking people with dementia: recommendations for practice. Int Psychogeriatr. 2012;24:358–66.PubMed
114.
go back to reference Sloane PD, Hoeffer B, Mitchell CM, et al. Effect of person-centered showering and the towel bath on bathing-associated aggression, agitation, and discomfort in nursing home residents with dementia: A randomized controlled trial. J Am Geriatr Soc. 2004;52:1795–804.PubMed Sloane PD, Hoeffer B, Mitchell CM, et al. Effect of person-centered showering and the towel bath on bathing-associated aggression, agitation, and discomfort in nursing home residents with dementia: A randomized controlled trial. J Am Geriatr Soc. 2004;52:1795–804.PubMed
115.
go back to reference Rosenberg PB, Mielke MM, Han D, et al. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer’s disease. Int J Geriatr Psychiatry. 2012. doi:10.1002/gps.3769 Rosenberg PB, Mielke MM, Han D, et al. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer’s disease. Int J Geriatr Psychiatry. 2012. doi:10.​1002/​gps.​3769
116.
go back to reference Lavretsky H. Neuropsychiatric symptoms in Alzheimer’s disease and related dementias: Why do treatments work in clinical practice but not in the randomized trials. Am J Geriatr Psychiatry. 2008;16:523–7.PubMed Lavretsky H. Neuropsychiatric symptoms in Alzheimer’s disease and related dementias: Why do treatments work in clinical practice but not in the randomized trials. Am J Geriatr Psychiatry. 2008;16:523–7.PubMed
117.
go back to reference Naarding P, van Grevenstein M, Beekman ATF. Benefit-risk analysis for the clinician: “primum non nocere” revisited – the case for antipsychotics in the treatment of behavioral disturbances in dementia. Int J Geriatr Psychiatry. 2010;25:437–40.PubMed Naarding P, van Grevenstein M, Beekman ATF. Benefit-risk analysis for the clinician: “primum non nocere” revisited – the case for antipsychotics in the treatment of behavioral disturbances in dementia. Int J Geriatr Psychiatry. 2010;25:437–40.PubMed
118.
go back to reference Devanand DP, Schultz SK. Consequences of antipsychotic medications for the dementia patient. Am J Psychiatry. 2011;168:767–9.PubMed Devanand DP, Schultz SK. Consequences of antipsychotic medications for the dementia patient. Am J Psychiatry. 2011;168:767–9.PubMed
119.
go back to reference Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson’s Disease. Report of a joint task force of the European Federation of Neurological Society (EFNS) and the Movement Disorder Society – European Section (MDS-ES). Part II: late (complicated) Parkinson’s disease. Eur J Neurol. 2006;13:1186–202.PubMed Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson’s Disease. Report of a joint task force of the European Federation of Neurological Society (EFNS) and the Movement Disorder Society – European Section (MDS-ES). Part II: late (complicated) Parkinson’s disease. Eur J Neurol. 2006;13:1186–202.PubMed
120.
go back to reference Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008;69:341–8.PubMed Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008;69:341–8.PubMed
121.
go back to reference Kerchner GA, Tartaglia MC, Boxer A. Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia. Expert Rev Neurother. 2011;11:709–17.PubMed Kerchner GA, Tartaglia MC, Boxer A. Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia. Expert Rev Neurother. 2011;11:709–17.PubMed
122.
go back to reference Howard RJ, Juszczak E, Ballard CG, et al. CALM-AD Trial Group: Donepezil for the treatment of agitation in Alzheimer’s disease. N Engl J Med. 2007;357:1382–92.PubMed Howard RJ, Juszczak E, Ballard CG, et al. CALM-AD Trial Group: Donepezil for the treatment of agitation in Alzheimer’s disease. N Engl J Med. 2007;357:1382–92.PubMed
123.
go back to reference Cummings JL, Schneider L, Tariot PN, et al. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer’s disease. Am J Psychiatry. 2004;161:532–8.PubMed Cummings JL, Schneider L, Tariot PN, et al. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer’s disease. Am J Psychiatry. 2004;161:532–8.PubMed
124.
go back to reference Vidal JS, et al. Evaluation of the impact of Memantine treatment initiation on psychotropics use: a study from the French national health care database. Neuroepidemiology. 2008;31:193–200.PubMed Vidal JS, et al. Evaluation of the impact of Memantine treatment initiation on psychotropics use: a study from the French national health care database. Neuroepidemiology. 2008;31:193–200.PubMed
125.
go back to reference Bannerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomized, multicenter, double-blind, placebo-controlled trial. Lancet. 2011;378:403–11. Bannerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomized, multicenter, double-blind, placebo-controlled trial. Lancet. 2011;378:403–11.
126.
go back to reference Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc. 2011;59:577–85.PubMed Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc. 2011;59:577–85.PubMed
127.
go back to reference Brodaty H. Antidepressant treatment in Alzheimer’s Disease. Lancet. 2011;378:375–6.PubMed Brodaty H. Antidepressant treatment in Alzheimer’s Disease. Lancet. 2011;378:375–6.PubMed
128.
go back to reference Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;(2):CD008191. Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;(2):CD008191.
129.
go back to reference Barak Y, Plopski I, Tadger S, Paleacu D. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer’s disease: a randomized double-blind pilot study. Int Psychogeriatr. 2011;23:1515–9. Barak Y, Plopski I, Tadger S, Paleacu D. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer’s disease: a randomized double-blind pilot study. Int Psychogeriatr. 2011;23:1515–9.
130.
go back to reference • Henry G, Williamson D, Tampi RR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26:169–83. Excellent review of evidence for the use of antidepressants to treat behavioral disturbances in patients with dementia.PubMed • Henry G, Williamson D, Tampi RR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26:169–83. Excellent review of evidence for the use of antidepressants to treat behavioral disturbances in patients with dementia.PubMed
131.
132.
go back to reference Wood LD, Neumiller JJ, Setter SM. Dobbins. Clinical review of treatment options for select nonmotor symptoms of Parkinson’s disease. Am J Geriatr Pharmacother. 2010;8:294–315.PubMed Wood LD, Neumiller JJ, Setter SM. Dobbins. Clinical review of treatment options for select nonmotor symptoms of Parkinson’s disease. Am J Geriatr Pharmacother. 2010;8:294–315.PubMed
133.
go back to reference Culo S, Mulsant BH, Rosen J, et al. Treating neuropsychiatric symptoms in dementia with lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord. 2010;24:360–4. Culo S, Mulsant BH, Rosen J, et al. Treating neuropsychiatric symptoms in dementia with lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord. 2010;24:360–4.
134.
go back to reference Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;19:1934–43. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;19:1934–43.
135.
go back to reference Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191–210.PubMed Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191–210.PubMed
136.
go back to reference US Food and Drug Administration. Deaths with antipsychotics in elderly patients with behavioral disturbances. Silver Spring: US Food and Drug Administration, Public Health Advisory, Center for Drug Evaluation and Research; 2005. US Food and Drug Administration. Deaths with antipsychotics in elderly patients with behavioral disturbances. Silver Spring: US Food and Drug Administration, Public Health Advisory, Center for Drug Evaluation and Research; 2005.
137.
go back to reference Jeste DV, Blazer D, Casey D, et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33:957–70.PubMed Jeste DV, Blazer D, Casey D, et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33:957–70.PubMed
138.
go back to reference Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2011;168:71–9. Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2011;168:71–9.
139.
go back to reference Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335–41.PubMed Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335–41.PubMed
140.
go back to reference Huybrechts KF, Rothman KJ, Silliman RA, et al. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ. 2010;183:E411–9. Huybrechts KF, Rothman KJ, Silliman RA, et al. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ. 2010;183:E411–9.
141.
go back to reference Vigen CLP, Mack WJ, Keefe RSE, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s Disease: Outcomes From CATIE-AD. Am J Psychiatry. 2011;168:831–9.PubMed Vigen CLP, Mack WJ, Keefe RSE, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s Disease: Outcomes From CATIE-AD. Am J Psychiatry. 2011;168:831–9.PubMed
142.
go back to reference Knol W, Marum RJV, Jansen PAF, et al. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc. 2008;56:661–6.PubMed Knol W, Marum RJV, Jansen PAF, et al. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc. 2008;56:661–6.PubMed
143.
go back to reference Ballard C, Hanney ML, Theodoulou M, et al. For the DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomized placebo-controlled trial. Lancet Neurol. 2009;8:151–7.PubMed Ballard C, Hanney ML, Theodoulou M, et al. For the DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomized placebo-controlled trial. Lancet Neurol. 2009;8:151–7.PubMed
144.
go back to reference Sultzer DL, Davis SM, Tariot PN, et al. CATIE-AD Study Group. Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165:844–54.PubMed Sultzer DL, Davis SM, Tariot PN, et al. CATIE-AD Study Group. Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165:844–54.PubMed
145.
go back to reference Zheng L, Mack WJ, Dagerman KS, et al. Metabolic changes associated with second-generation antipsychotic use in Alzheimer’s disease patients: the CATIE-AD study. Am J Psychiatry. 2009;166:583–90.PubMed Zheng L, Mack WJ, Dagerman KS, et al. Metabolic changes associated with second-generation antipsychotic use in Alzheimer’s disease patients: the CATIE-AD study. Am J Psychiatry. 2009;166:583–90.PubMed
146.
go back to reference Devanand DP, Pelton GH, Cunqueiro K, Sackeim HA, Marder K. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer’s disease. Int J Geriatr Psychiatry. 2011;26:937–43.PubMed Devanand DP, Pelton GH, Cunqueiro K, Sackeim HA, Marder K. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer’s disease. Int J Geriatr Psychiatry. 2011;26:937–43.PubMed
147.
go back to reference Leon C, Gerretsen P, Uchida H, et al. Sensitivity to antipsychotic drugs in older adults. Curr Psychiatry Rep. 2010;12:28–33.PubMed Leon C, Gerretsen P, Uchida H, et al. Sensitivity to antipsychotic drugs in older adults. Curr Psychiatry Rep. 2010;12:28–33.PubMed
148.
go back to reference Corbett A, Ballard C. Antipsychotics and mortality in dementia. Am J Psychiatry. 2011;169:7–9. Corbett A, Ballard C. Antipsychotics and mortality in dementia. Am J Psychiatry. 2011;169:7–9.
149.
go back to reference Profenno LA, Tariot PN. Pharmacologic management of agitation in Alzhiemer’s disease. Dement Geriatr Cogn Disord. 2004;17:65–77.PubMed Profenno LA, Tariot PN. Pharmacologic management of agitation in Alzhiemer’s disease. Dement Geriatr Cogn Disord. 2004;17:65–77.PubMed
150.
go back to reference Llorente M, Urrutia V. Diabetes, psychiatric disorders, and the metabolic effects of antipsychotic medications. Clin Diabetes. 2006;24:18–24. Llorente M, Urrutia V. Diabetes, psychiatric disorders, and the metabolic effects of antipsychotic medications. Clin Diabetes. 2006;24:18–24.
151.
go back to reference Baskys A. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry. 2004;65 Suppl 11:16–22.PubMed Baskys A. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry. 2004;65 Suppl 11:16–22.PubMed
152.
go back to reference Mitchell SL, Teno JM, Kiely DK, et al. The clinical course of advanced dementia. N Engl J Med. 2009;361:1529–38.PubMed Mitchell SL, Teno JM, Kiely DK, et al. The clinical course of advanced dementia. N Engl J Med. 2009;361:1529–38.PubMed
153.
go back to reference Dolder CR, Nealy KL, McKinsey J. Valproic acid in dementia: does an optimal dose exist? J Pharm Pract. 2012;25:142–50.PubMed Dolder CR, Nealy KL, McKinsey J. Valproic acid in dementia: does an optimal dose exist? J Pharm Pract. 2012;25:142–50.PubMed
154.
go back to reference Olin JT, Fox LS, Pawluczyk S, et al. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry. 2001;9:400–5.PubMed Olin JT, Fox LS, Pawluczyk S, et al. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry. 2001;9:400–5.PubMed
155.
go back to reference Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155:54–61.PubMed Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155:54–61.PubMed
156.
go back to reference Sommer BR, Fenn HH, Ketter TA. Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbamazepine, topiramate and gabapentin. Expert Opin Drug Saf. 2007;6:133–45.PubMed Sommer BR, Fenn HH, Ketter TA. Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbamazepine, topiramate and gabapentin. Expert Opin Drug Saf. 2007;6:133–45.PubMed
157.
go back to reference Kim Y, Wilkins KM, Tampi RR. Use of gabapentin in the treatment of behavioral and psychological symptoms of dementia: a review of the evidence. Drugs Aging. 2008;25:187–96.PubMed Kim Y, Wilkins KM, Tampi RR. Use of gabapentin in the treatment of behavioral and psychological symptoms of dementia: a review of the evidence. Drugs Aging. 2008;25:187–96.PubMed
158.
go back to reference Ng B, Camacho A, Bardwell W, et al. Lamotrigine for agitation in older patients with dementia. Int Psychogeriatr. 2009;21:207–8.PubMed Ng B, Camacho A, Bardwell W, et al. Lamotrigine for agitation in older patients with dementia. Int Psychogeriatr. 2009;21:207–8.PubMed
159.
go back to reference Kushnir SL. Lithium-antidepressant combinations in the treatment of depressed, physically ill geriatric patients. Am J Psychiatry. 1986;143:378–9.PubMed Kushnir SL. Lithium-antidepressant combinations in the treatment of depressed, physically ill geriatric patients. Am J Psychiatry. 1986;143:378–9.PubMed
160.
go back to reference Teri L, et al. Alzheimer’s Disease Cooperative Study: Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55:1271–8.PubMed Teri L, et al. Alzheimer’s Disease Cooperative Study: Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55:1271–8.PubMed
161.
go back to reference Lawlor BA, Radcliffe J, Molchan SA, et al. A pilot placebo-controlled study of trazodone and buspirone in Alzheimer’s disease. Int J Geriatr Psychiatry. 1994;9:55–9. Lawlor BA, Radcliffe J, Molchan SA, et al. A pilot placebo-controlled study of trazodone and buspirone in Alzheimer’s disease. Int J Geriatr Psychiatry. 1994;9:55–9.
162.
go back to reference Stevenson DG, Decker SL, Dwyer LL, et al. Antipsychotic and benzodiazepine use among nursing home residents: findings from the 2004 National Nursing Home Survey. Am J Geriatr Psychiatry. 2010;18:1078–92.PubMed Stevenson DG, Decker SL, Dwyer LL, et al. Antipsychotic and benzodiazepine use among nursing home residents: findings from the 2004 National Nursing Home Survey. Am J Geriatr Psychiatry. 2010;18:1078–92.PubMed
163.
go back to reference Bourgeois J, Elseviers MM, Azermai M, et al. Benzodiazepine use in Belgian nursing homes: a closer look into indications and dosages. Eur J Clin Pharmacol. 2012;68:833–44.PubMed Bourgeois J, Elseviers MM, Azermai M, et al. Benzodiazepine use in Belgian nursing homes: a closer look into indications and dosages. Eur J Clin Pharmacol. 2012;68:833–44.PubMed
164.
go back to reference Neugroschl J, Wang S. Alzheimer’s Disease: Diagnosis and treatment across the spectrum of disease severity. Mt Sinai J Med. 2011;78:596–612.PubMed Neugroschl J, Wang S. Alzheimer’s Disease: Diagnosis and treatment across the spectrum of disease severity. Mt Sinai J Med. 2011;78:596–612.PubMed
165.
go back to reference Wang LY, Shofer JB, Rohde K, et al. Prazosin for the treatment of behavioral symptoms in Alzheimer’s disease patients with agitation and aggression. Am J Geriatr Psychiatry. 2009;17:744–51.PubMed Wang LY, Shofer JB, Rohde K, et al. Prazosin for the treatment of behavioral symptoms in Alzheimer’s disease patients with agitation and aggression. Am J Geriatr Psychiatry. 2009;17:744–51.PubMed
166.
go back to reference Peskind ER, Tsuang DW, Bonner LT, et al. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. Alzheimer Dis Assoc Disord. 2005;19:23–8.PubMed Peskind ER, Tsuang DW, Bonner LT, et al. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. Alzheimer Dis Assoc Disord. 2005;19:23–8.PubMed
167.
go back to reference Kraus MF, Maki PM. Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. J Neuropsychiatry Clin Neurosci. 1997;9:222–30.PubMed Kraus MF, Maki PM. Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. J Neuropsychiatry Clin Neurosci. 1997;9:222–30.PubMed
168.
go back to reference Kyomen HH, Satlin A, Hennen J, et al. Estrogen therapy and aggressive behavior in elderly patients with moderate-to-severe dementia: results from a short-term, randomized double-blind trial. Am J Geriatr Psychiatry. 1999;7:339–48.PubMed Kyomen HH, Satlin A, Hennen J, et al. Estrogen therapy and aggressive behavior in elderly patients with moderate-to-severe dementia: results from a short-term, randomized double-blind trial. Am J Geriatr Psychiatry. 1999;7:339–48.PubMed
169.
go back to reference Desai AK, Grossberg GT. Buspirone in Alzheimer’s disease. Exp Rev Neurother. 2003;3:19–28. Desai AK, Grossberg GT. Buspirone in Alzheimer’s disease. Exp Rev Neurother. 2003;3:19–28.
170.
go back to reference Gehrman PR, Connor DJ, Martin JL, et al. Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer’s disease. Am J Geriatr Psychiatry. 2009;17:166–9.PubMed Gehrman PR, Connor DJ, Martin JL, et al. Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer’s disease. Am J Geriatr Psychiatry. 2009;17:166–9.PubMed
171.
go back to reference Rao V, Lyketsos CG. The benefits and risks of ECTs for patients with primary dementia who also suffer from depression. Int J Geriatr Psychiatry. 2000;15:729–35.PubMed Rao V, Lyketsos CG. The benefits and risks of ECTs for patients with primary dementia who also suffer from depression. Int J Geriatr Psychiatry. 2000;15:729–35.PubMed
172.
go back to reference Ujkaj M, Davidoff DA, Seiner SJ, et al. Safety and efficacy of electroconvulsive therapy for the treatment of agitation and aggression in patients with dementia. Am J Geriatr Psychiatry. 2012;20:61–72.PubMed Ujkaj M, Davidoff DA, Seiner SJ, et al. Safety and efficacy of electroconvulsive therapy for the treatment of agitation and aggression in patients with dementia. Am J Geriatr Psychiatry. 2012;20:61–72.PubMed
173.
go back to reference Salzman C, Jeste DV, Meyer RE, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry. 2008;69:889–98.PubMed Salzman C, Jeste DV, Meyer RE, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry. 2008;69:889–98.PubMed
174.
go back to reference Husebo BS, Ballard C, Aarsland D. Pain treatment of agitation in patients with dementia: a systematic review. Int J Geriatr Psychiatry. 2011;26:1012–8.PubMed Husebo BS, Ballard C, Aarsland D. Pain treatment of agitation in patients with dementia: a systematic review. Int J Geriatr Psychiatry. 2011;26:1012–8.PubMed
175.
go back to reference Hori K, Konishi K, Watanabe K, et al. Influence of anticholinergic activity in serum on clinical symptoms of Alzheimer’s disease. Neuropsychobiology. 2011;63:147–53.PubMed Hori K, Konishi K, Watanabe K, et al. Influence of anticholinergic activity in serum on clinical symptoms of Alzheimer’s disease. Neuropsychobiology. 2011;63:147–53.PubMed
Metadata
Title
Behavioral Disturbance in Dementia
Authors
Abhilash K. Desai
Lori Schwartz
George T. Grossberg
Publication date
01-08-2012
Publisher
Current Science Inc.
Published in
Current Psychiatry Reports / Issue 4/2012
Print ISSN: 1523-3812
Electronic ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-012-0288-5

Other articles of this Issue 4/2012

Current Psychiatry Reports 4/2012 Go to the issue

Eating Disorders (E Attia, Section Editor)

Beyond Picky Eating: Avoidant/Restrictive Food Intake Disorder

Eating Disorders (E Attia, Section Editor)

Adolescent Bulimia Nervosa

Psychiatry in Primary Care (BN Gaynes, Section Editor)

Cross-Cultural Aspects of Depression Management in Primary Care

Eating Disorders (E Attia, Section Editor)

Psychological Treatments for Binge Eating Disorder

Geriatric Disorders (DC Steffens, Section Editor)

Depression and Cognitive Impairment in Older Adults